Living

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports

By Reuters Reuters
Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe
Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe Chris J Ratcliffe Reuters

UK pharmaceutical group GSK is in talks to buy cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported on Monday, citing people familiar with the matter.

Reuters could not immediately verify the report.

(Reporting by Angela Christy in Bengaluru; )

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 8, 2026 at 8:15 PM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER